CoChat
Sign Up
Cited by 284Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

Open access
Schindler, Suzanne E., Gray, Julia D., Gordon, Brian A., Xiong, Chengjie, Batrla‐Utermann, Richard, Quan, Marian, Wahl, Simone, Benzinger, Tammie L.S. +3 more·2018·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2018.01.013PMC PMC6119652
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau‐181 are well‐established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but variability in manual plate‐based assays has limited their use. We examined the relationship between CSF biomarkers, as measured by a novel automated immunoassay platform, and amyloid positron emission tomography. Methods: CSF samples from 200 individuals underwent separate analysis for Aβ42, total tau, and phosphorylated tau‐181 with automated Roche Elecsys assays. Aβ40 was measured with a commercial plate‐based assay. Positron emission tomography with Pittsburgh Compound B was performed less than 1 year from CSF collection. Results: Ratios of CSF biomarkers (total tau/Aβ42, phosphorylated tau‐181/Aβ42, and Aβ42/Aβ40) best discriminated Pittsburgh Compound B–positive from Pittsburgh Compound B–negative individuals. Discussion: CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less‐than‐perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.01.013

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In previous studies, the FDA-approved Elecsys CSF p-tau181/Aβ42 test classified Aβ PET status with overall accuracies of 89-90%.

    “For instance, the FDA-approved Elecsys CSF p-tau181/Aβ42 test has, in previous studies, classified Aβ PET status with overall accuracies of 89–90% (refs. 39–41), which was replicated in the present study.”

    From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [40]

    Results §3.3 (page unavailable) reports that the Elecsys pTau/Aβ42 ratio distinguished amyloid PET status and gives agreement ranges for the CSF ratios. Our copy does not establish the specific 89–90% overall accuracy for pTau/Aβ42 or describe the test as FDA-approved; Methods §2.4 says some measured values were restricted to research use. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 50 · Cited by 284

Research works printed but not linked: 39

  1. [1]Price JL Morris JC Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease Annals of neurology 1999 45 358 68 10072051
  2. [4]Bateman RJ Xiong C Benzinger TL Fagan AM Goate A Fox NC Clinical and biomarker changes in dominantly inherited Alzheimer’s disease The New England journal of medicine 2012 367 795 804 22784036 PMC3474597
  3. [5]Fagan AM Mintun MA Mach RH Lee SY Dence CS Shah AR Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Annals of neurology 2006 59 512 9 16372280
  4. [6]Fagan AM Mintun MA Shah AR Aldea P Roe CM Mach RH Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease EMBO molecular medicine 2009 1 371 80 20049742 PMC2806678
  5. [7]Fagan AM Roe CM Xiong C Mintun MA Morris JC Holtzman DM Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 2007 64 343 9 17210801
  6. [8]Li G Sokal I Quinn JF Leverenz JB Brodey M Schellenberg GD CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 2007 69 631 9 17698783
  7. [9]Duits FH Teunissen CE Bouwman FH Visser PJ Mattsson N Zetterberg H The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2014 10 713 23e2 24721526
  8. [10]Brys M Pirraglia E Rich K Rolstad S Mosconi L Switalski R Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment Neurobiology of aging 2009 30 682 90 17889968 PMC2774781
  9. [11]Hansson O Zetterberg H Buchhave P Londos E Blennow K Minthon L Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study The Lancet Neurology 2006 5 228 34 16488378
  10. [12]Shaw LM Vanderstichele H Knapik-Czajka M Figurski M Coart E Blennow K Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI Acta neuropathologica 2011 121 597 609 21311900 PMC3175107
  11. [14]Molinuevo JL Blennow K Dubois B Engelborghs S Lewczuk P Perret-Liaudet A The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2014 10 808 17 25150736
  12. [15]Morris JC Selkoe DJ Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview Neurobiology of aging 2011 32 Suppl 1 S1 3 22078168
  13. [16]Hampel H Wilcock G Andrieu S Aisen P Blennow K Broich K Biomarkers for Alzheimer’s disease therapeutic trials Progress in neurobiology 2011 95 579 93 21130138
  14. [17]Wang J Tan L Yu JT Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives Journal of Alzheimer’s disease: JAD 2016 50 927 45 26836177
  15. [18]Sperling RA Rentz DM Johnson KA Karlawish J Donohue M Salmon DP The A4 study: stopping AD before symptoms begin? Science translational medicine 2014 6 228fs13 PMC4049292 24648338
  16. [19]Galasko D Chang L Motter R Clark CM Kaye J Knopman D High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype Arch Neurol 1998 55 937 45 9678311
  17. [20]Frisoni GB Bocchetta M Chetelat G Rabinovici GD de Leon MJ Kaye J Imaging markers for Alzheimer disease: which vs how Neurology 2013 81 487 500 23897875 PMC3776529
  18. [21]Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Annals of neurology 2004 55 306 19 14991808
  19. [22]Witte MM Foster NL Fleisher AS Williams MM Quaid K Wasserman M Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations Alzheimer’s & dementia 2015 1 358 67 PMC4878065 27239516
  20. [23]O’Brien JT Herholz K Amyloid imaging for dementia in clinical practice BMC medicine 2015 13 163 26170121 PMC4499896
  21. [24]Lewczuk P Matzen A Blennow K Parnetti L Molinuevo JL Eusebi P Cerebrospinal Fluid Abeta42/40 Corresponds Better than Abeta42 to Amyloid PET in Alzheimer’s Disease Journal of Alzheimer’s disease: JAD 2017 55 813 22 27792012 PMC5147502
  22. [25]Grimmer T Riemenschneider M Forstl H Henriksen G Klunk WE Mathis CA Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biological psychiatry 2009 65 927 34 19268916 PMC2700302
  23. [26]Jagust WJ Landau SM Shaw LM Trojanowski JQ Koeppe RA Reiman EM Relationships between biomarkers in aging and dementia Neurology 2009 73 1193 9 19822868 PMC2764726
  24. [27]Landau SM Lu M Joshi AD Pontecorvo M Mintun MA Trojanowski JQ Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid Annals of neurology 2013 74 826 36 23536396 PMC3748164
  25. [28]Mattsson N Insel PS Landau S Jagust W Donohue M Shaw LM Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer’s disease Annals of clinical and translational neurology 2014 1 534 43 25356425 PMC4184556
  26. [31]Tolboom N van der Flier WM Yaqub M Boellaard R Verwey NA Blankenstein MA Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2009 50 1464 70 19690025
  27. [32]Fagan AM Shaw LM Xiong C Vanderstichele H Mintun MA Trojanowski JQ Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology Arch Neurol 2011 68 1137 44 21555603 PMC3154969
  28. [33]Vos SJB Gordon BA Su Y Visser PJ Holtzman DM Morris JC NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers Neurobiology of aging 2016 44 1 8 27318129 PMC4913039
  29. [34]Vos SJ Visser PJ Verhey F Aalten P Knol D Ramakers I Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice PloS one 2014 9 e100784 24959687 PMC4069102
  30. [35]Mattsson N Andreasson U Persson S Arai H Batish SD Bernardini S The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2011 7 386 95 e6 PMC3710290 21784349
  31. [36]Mattsson N Andreasson U Persson S Carrillo MC Collins S Chalbot S CSF biomarker variability in the Alzheimer’s Association quality control program Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2013 9 251 61 PMC3707386 23622690
  32. [37]Schindler SE Sutphen CL Teunissen C McCue LM Morris JC Holtzman DM Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2017 PMC5750131 28710906
  33. [38]Mattsson N Zegers I Andreasson U Bjerke M Blankenstein MA Bowser R Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomarkers in medicine 2012 6 409 17 22917143
  34. [40]Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 1993 43 2412 4 8232972
  35. [43]Mintun MA Larossa GN Sheline YI Dence CS Lee SY Mach RH [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006 67 446 52 16894106
  36. [44]Fischl B van der Kouwe A Destrieux C Halgren E Segonne F Salat DH Automatically parcellating the human cerebral cortex Cerebral cortex 2004 14 11 22 14654453
  37. [47]Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doraiswamy PM Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study The Lancet Neurology 2012 11 669 78 22749065
  38. [48]Cairns NJ Ikonomovic MD Benzinger T Storandt M Fagan AM Shah AR Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch Neurol 2009 66 1557 62 20008664 PMC2796200
  39. [49]Sperling RA Aisen PS Beckett LA Bennett DA Craft S Fagan AM Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimer’s & dementia: the journal of the Alzheimer’s Association 2011 7 280 92 PMC3220946 21514248

Authors
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., & Fagan, A. M.
Affiliations
  • Washington University in St. Louis (US)
  • F. Hoffmann-La Roche AG (CH)
  • Roche Diagnostics Indianapolis IN USA
  • Roche Diagnostics GmbH Penzberg Germany
Corresponding author
Fagan, Anne M.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2018-03
Volume
14
Issue
11
Pages
1460-1469
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2018.01.013
PMC
PMC6119652
OpenAlex
W2792820766
Cited by
284
References
50
Citations by year
2026: 16 · 2025: 35 · 2024: 38 · 2023: 34 · 2022: 44 · 2021: 42 · 2020: 38 · 2019: 28 · 2018: 7
FWCI
22.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
Funders
  • National Institute on Aging (P01AG026276, P01AG03991, P50AG05681)
  • Barnes Jewish Hospital Foundation (P30NS098577, R01EB009352, UL1TR000448)
  • National Institutes of Health (K23AG053426, R03AG050921)
  • NIH (R01AG034119, R01AG053550, P50AG005681, P01AG003991, P01AG026276, UF01AG032438, UF01AG03243807)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
cerebrospinal fluid biomarkers, Alzheimer's disease
MeSH terms
Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Female, Humans, Immunoassay, Male, Middle Aged, Peptide Fragments, Thiazoles, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Radiopharmaceuticals, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review